Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation is a research paper published in Cancer Discovery (2021). On theSindex it has a DataRank of 0. It has been cited 520 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Revolution Medicines
Grant: RM-018
Stand Up To Cancer—American Cancer Society Lung Cancer Dream Team Translational Research Grant
Grant: SU2C-AACR-DT17–15
NIH
Grant: R01-CA164273
NIH
Grant: 1F32CA250231–01
AACR
Grant: 19–20–45-BARP
Damon Runyon
Grant: DRR-62–20
NIH NCI
Grant: R00 CA215249
NCI NIH HHS
Grant: U54 CA224068
NCI NIH HHS
Grant: R01 CA164273
NCI NIH HHS
Grant: R01 CA208437
NCI NIH HHS
Grant: F32 CA250231
NCI NIH HHS
Grant: R37 CA260062
FWCI
26.60
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination